Ulcerative Colitis

What it is

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by continuous inflammation and ulceration of the colon and rectum. UC typically begins in the rectum and extends proximally to varying degrees. Common symptoms include bloody diarrhea, abdominal pain, urgency, tenesmus, fatigue, and weight loss. Disease severity ranges from limited ulcerative proctitis to pancolitis affecting the entire colon. Extra-intestinal manifestations include arthritis, uveitis, primary sclerosing cholangitis, and erythema nodosum. Long-standing UC increases colorectal cancer risk.

UC is one of two major forms of inflammatory bowel disease, the other being Crohn's disease. Both share some treatment overlap but UC is anatomically restricted to the colon and produces continuous (rather than skip-pattern) inflammation.

Cannabis and cannabis-derived therapies

Cannabis evidence for UC is limited at the disease-activity level. Small randomized trials have shown improvement in patient-reported symptoms with cannabis or cannabinoid preparations, but objective measures (endoscopic healing, biomarker reduction, clinical remission rates) have not consistently improved.

The 2017 NASEM consensus report did not identify high-tier evidence for cannabis as a treatment for IBD. Preclinical work on the endocannabinoid system in intestinal inflammation has been active for over a decade. CB1 and CB2 receptors are expressed throughout the gastrointestinal tract, and modulation has shown effects in animal colitis models, but translation to human disease-modifying therapy has not occurred.

Practical considerations

Cannabis should be used adjunctively rather than as a substitute for 5-aminosalicylates, biologics, or other UC-modifying therapy. Patients should coordinate cannabis use with their gastroenterologist, particularly when also taking immunomodulators or biologics.

Smoked cannabis can have variable effects on the gastrointestinal tract and is sometimes associated with increased nausea in IBD patients. Oral, sublingual, and rectal cannabinoid preparations have been studied in small trials with potentially better tolerability. Cannabis hyperemesis syndrome (paradoxical severe cyclic vomiting in heavy chronic cannabis users) can be difficult to distinguish from UC flare in symptom presentation.

Important: ulcerative colitis is a progressive disease with significant long-term risks (colorectal cancer, severe flares, surgical intervention). Patients should not substitute cannabis for prescribed UC-modifying therapy or skip endoscopic surveillance.